(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...
Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...
JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member ...
Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...
By pausing DMARDs, you may be ‘starting the cascade of getting the patient into trouble by interrupting therapy that’s ...
SEOUL, April 1 (Yonhap) -- South Korean stocks traded fairly higher late Tuesday morning as investors hunted for profit ...
Bond prices, which move inversely to yields, ended higher. The yield on three-year Treasurys fell 6 basis points to 2.569 ...
Korean won falls to two-month low as foreign outflows, tariff fears weigh on markets While short selling resumed in South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback